Published in AIDS on June 19, 2014
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med (2016) 3.82
Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. J Acquir Immune Defic Syndr (2015) 1.32
A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film. J Acquir Immune Defic Syndr (2016) 0.95
Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa. PLoS One (2016) 0.91
Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Drugs (2015) 0.90
Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings. J Int AIDS Soc (2016) 0.83
Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. J Control Release (2015) 0.83
Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence. J Pharm Biomed Anal (2016) 0.83
Investigational reverse transcriptase inhibitors for the treatment of HIV. Expert Opin Investig Drugs (2015) 0.78
Levonorgestrel in contraceptives and multipurpose prevention technologies: does this progestin increase HIV risk or interact with antiretrovirals? AIDS (2016) 0.78
Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals on Failing First-Line Antiretroviral Therapy in South Africa. Antimicrob Agents Chemother (2016) 0.78
Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B). AIDS Res Hum Retroviruses (2016) 0.77
Abolishing HIV-1 infectivity using a polypurine tract-specific G-quadruplex-forming oligonucleotide. BMC Infect Dis (2016) 0.75
Pharmacokinetics of the protein microbicide 5P12-RANTES in sheep following single dose vaginal gel administration. Antimicrob Agents Chemother (2017) 0.75
In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of HIV-1 Infection. Antimicrob Agents Chemother (2017) 0.75
Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial. J Acquir Immune Defic Syndr (2017) 0.75
Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS (2003) 1.95
Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr (2009) 1.89
Advances in microbicide vaginal rings. Antiviral Res (2010) 1.76
HIV incidence among women of reproductive age in Malawi and Zimbabwe. Sex Transm Dis (2006) 1.75
Topical microbicides for disease prevention: status and challenges. Clin Infect Dis (2003) 1.58
The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol (2005) 1.54
Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob Agents Chemother (2011) 1.48
Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses (2010) 1.44
Predictors of herpes simplex virus type 2 prevalence and incidence among bar and hotel workers in Moshi, Tanzania. J Infect Dis (2007) 1.33
Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med (2012) 1.31
HIV incidence remains high in KwaZulu-Natal, South Africa: evidence from three districts. PLoS One (2012) 1.23
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother (2008) 1.16
The future of HIV microbicides: challenges and opportunities. Antivir Chem Chemother (2009) 1.13
Development of dapivirine vaginal ring for HIV prevention. Antiviral Res (2013) 1.07
The future of HIV prevention: prospects for an effective anti-HIV microbicide. Infect Dis Clin North Am (2007) 0.99
A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol (2008) 0.94
A generalized Sidak-Holm procedure and control of generalized error rates under independence. Stat Appl Genet Mol Biol (2007) 0.90
Biosensor for dengue virus detection: sensitive, rapid, and serotype specific. Anal Chem (2002) 0.88
Characterization of vaginal transmission of a simian human immunodeficiency virus (SHIV) encoding the reverse transcriptase gene from HIV-1 in Chinese rhesus macaques. Virology (2009) 0.87
Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide. Antimicrob Agents Chemother (2012) 0.86
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol (2007) 0.83
Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers. J Am Coll Cardiol (2016) 0.82
Recent work on vaginal rings containing antiviral agents for HIV prevention. Curr Opin HIV AIDS (2015) 0.79
Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of betaII tryptase. Bioorg Med Chem (2005) 0.76
Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates. AIDS (2016) 0.75